A comparison of Re-188-MN-16ET-lipiodol and transcatheter arterial chemoembolization in the treatment of hepatoma: An animal study |
| |
Authors: | Wan-Yu Lin Tsai-Yueh Luo Shih-Chung Tsai Chia-Hung Kao I-Chung Tang Ping-Wun Huang |
| |
Institution: | 1. Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan;2. School of Medicine, China Medical University, Taichung, Taiwan;3. Institute of Radiological Science, Central Taiwan University of Science and Technology, Taichung 406, Taiwan;4. Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan County, Taiwan;5. Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan.;6. Department of Emergency Medicine, Show-Chwan Memorial Hospital, 542, Sec. 1, Chung-Shan Rd., Changhua 500, Taiwan |
| |
Abstract: | IntroductionIn patients with unresectable HCC, transcatheter arterial chemoembolization (TACE) is a widely used treatment. Recently, as an alternative treatment modality for HCC, transcatheter arterial embolization with radioisotopes has been investigated. In this study, we compared the therapeutic efficacy of an intra-hepatic arterial injection of Re-188-MN-16ET-lipiodol and the TACE method in rats with liver tumors.MethodsTwelve male rats bearing hepatic tumors were divided into three groups to evaluate the efficacy of treatment (four in each group). Group 1 received an intra-hepatic arterial injection of 0.2 mCi of Re-188-MN-16ET-lipiodol; group 2 received epirubicin (0.5 mg/kg) and 0.1 ml of lipiodol emulsion; group 3 received 0.1 ml of normal saline and served as the control group. Tumor size was measured by liver sonography before injection, at two weeks, four weeks and eight weeks after injection. Survival time was calculated from the day of treatment to 56 days after treatment by the life-table method. The response to treatment and the survival time in each group were evaluated and compared.ResultsAll rats treated with Re-188 MN-16ET-lipiodol showed good response to the therapy. Their tumor size decreased and all rats survived over eight weeks. All rats treated with epirubicin plus lipiodol survived over 8 weeks; however, two rats (50%) showed increased tumor size in the 8th week. As for the control group (rats treated with normal saline), all rats survived less than 37 days with continuous tumor growth.ConclusionResults showed that Re-188-MN-16ET-lipiodol can be a potential therapeutic pharmaceutical for the treatment of liver tumors. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|